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Objective: Dietary soy may improve menopausal symptoms, and subsequently 
mediate mood. This novel study examines various does of dietary soy drink on 
everyday mood stability and variability in postmenopausal women. Methods: 
Community dwelling women (n=101), within 7 years post menopause consumed daily 
either a low (10mg, n=35), medium (35mg, n=37) or high (60mg, n=29) dose of 
isoflavones, for twelve weeks.  Menopausal symptoms and repeated measures of 
everyday Mood (Positive (PA) and Negative (NA) affect) (assessed at four time points 
per day for four consecutive days, using PANAS) were completed at baseline and 
follow up. Results: The dietary soy intervention had no effect on everyday mood 
stability (for PA (F(2,70) = .95, p = .390) and NA (F(2,70) = 0.72, p = .489) or variability 
(for PA (F(2,70) = .21, p = .807) and for NA (F(2,70) = .15, p=.864) or on menopausal 
symptoms (for vasomotor (F (2,89) = 2.83, p = .064), psychological (F (2,88) = 0.63, p 
= .535), somatic (F (2,89) = 0.32, p =.729) and total menopausal symptoms (F (2,86) 
= 0.79, p = .458)). There were between group differences with the medium dose 
reporting higher PA (low, mean: 24.2, SD: 6 and medium, mean: 29.7, SD: 6) and the 
low dose reporting higher NA (P = 0. 048) (Low, mean: 11.6, SD: 2 and high, mean: 
10.6, SD: 1) in mood scores. Psychological (baseline M = 18 and follow up M = 16.5) 
and vasomotor (baseline M = 4.2 and follow up M = 3.6) scores declined from baseline 
to follow up for the overall sample. Conclusions: Soy isoflavones had no effect on 
mood at any of the doses tested. Future research should focus on the menopausal 
transition from peri to post menopause as there may be a window of vulnerability, with 
fluctuating hormones and increased symptoms which may affect mood. 
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INTRODUCTION 
 The menopausal transition (MT) may impact on mood due to increased 
vasomotor symptoms1,2 and psychosocial changes at MT3-5, leading to a decline in 
well-being6.  Fluctuations in mood at MT have been associated with hormonal changes 
in some studies7 but contested in others (for a review see Hengartner, 20178), 
suggesting the underlying processes are not well understood9,10. There are no specific 
mood disorders of the menopause4. Treatment of mood disorders occurring during MT 
with hormone therapy (HT) has produced conflicting results11,12.  
 The few studies looking at mood and MT have suggested differential effects on 
positive (PA) and negative (NA) mood13.   PA was not influenced by MT in one study14, 
but NA was related to the severity of menopausal symptoms and stage of MT, the 
closer to MT the greater the impact of symptoms on NA15, further supported by 
longitudinal research16. One other study reported elevated menopausal symptoms 
was detrimental to PA17, while another reported increased NA and a decline in PA18. 
The conflicting findings may be due to methodological issues around how and when 
mood was measured, samples vary in relation to age and menopausal status. Moods 
fluctuate and change throughout the day and need to be assessed using repeated 
measures19. In the current study mood or affect was regarded as a subjective state 
conceptualized as two independent continua, positive affect (PA) and negative affect 
(NA)20,21. PA reflects states such as joy, alertness, and enthusiasm, while NA 
measures the amount of unpleasantness or dissatisfaction the person is 
experiencing22. 
 Vasomotor symptoms respond well to HT, however, due to increased fears 
around its use23, the number of women using HT and doctors prescribing it has 
declined. This has led to women seeking out alternatives to HT24, of which soy is one. 
Soy contains a high concentration of isoflavones, regarded as plant-based 
phytoestrogens, including genistein, daidzein and glycitein, which have a similar 
chemical structure to 17-β estradiol25, binding to estrogen receptors and mimicking 
their effects26. They are recommended for management of vasomotor symptoms27. 
Isoflavones have several health benefits for MT such as promoting heart health, bone 
mass and alleviation of vasomotor symptoms28,29. Some soy isoflavones, such as 
glyceollins, have been found to produce insulinotropic, antiestrogenic, 
antiproliferation, antioxidant, anti-inflammatory and cholesterol lowering effects in 
women at midlife30. Their impact on psychological factors at MT are less clear. 
 Dietary soy products were found to reduce psychological symptoms and 
improve well-being in menopausal women. In a 6-week intervention participants 
consumed 200ml soy drink per day, with improvements in menopausal symptoms and 
quality of life31. Positive effects were noted for a soy drink (12.5 g of soy protein with 
genistein, 13 mg and daidzein, 4.13 mg day) and an exercise intervention32 improving 
menopausal symptoms and psychological well-being. These findings were further 
supported by reviews of soy products13,33. However, several studies reported no 
beneficial effects after a six-month dietary soy intervention (100mg isoflavones in flour) 
for depressive symptoms34, or a three month intervention for menopausal symptoms 
(118 mg of isoflavones in supplement)35 or 8 months consumption of 500ml of soy 
drink per day (containing 28.86 mg/dl of genistein and 8.25 mg/dl of daidzein) on 
quality of life36 in menopausal women. Mood tends to be assessed using symptom 
scales or visual analogue scales, in the few studies that have looked at mood during 
menopause, rather than by repeated measures employing scales designed to capture 
mood change. 
 To our knowledge this is the first study to look at the effect of a 12-week dietary 
soy intervention on everyday PA and NA stability and variability in postmenopausal 
women. The first objective was to examine if PA and NA were influenced pre to post 
intervention.  The second objective was to determine the effect on mood with different 
concentrations of isoflavones consumed over time.  
 
METHODS 
Study design & Participants 
 This study was a 12-week prospective randomized trial, conducted between 
October 2015 and May 2018, looking at the effect of a soy drink intervention on 
cognitive function (results will be reported elsewhere), menopausal symptoms and 
everyday PA and NA in postmenopausal women. Following ethical approval from the 
University Research Ethics Committee, women were recruited from community groups 
and organizations throughout Ulster, an overview of this process is given in the flow 
chart in Figure 1.  All the participants were required to be within seven years 
postmenopausal, defined using the WHO definition, as cessation of menses for at 
least 12 months at hormone levels >30 mIU/ml for follicle stimulating hormone. They 
were excluded if taking HT, had an abnormal blood profile (assessed by Sysmex 
KX21-N, Sysmex UK Ltd, Milton Keynes, UK) and liver and kidney function tests 
(assessed photometrically by Cobas 6000 analyzer [Cobas C501 module], Roche 
Diagnostics at Causeway Hospital, Coleraine, UK), had a hysterectomy and 
ovariectomy, were taking antibiotics or psychoactive medication, and if they had a 
history of cardiovascular disease, cancer, diabetes, thyroid, renal or kidney disease, 
alcohol or drug abuse. Self-reported consumption of soy-based products beyond two 
portions per week was also an exclusion criterion. 
 Participants were also screened for cognitive decline and psychological 
distress as determined by the Mini Mental State Examination (scores less than 24 
were excluded) and General Health Questionnaire-28 (adopting 26 as the threshold 
for the presence of distress), respectively. 
 Those eligible, were invited for baseline measures on mood (PANAS to be 
completed over 4 days prior to beginning the soy drink intervention) and menopausal 
symptoms. They were then randomly allocated to one of three conditions a low (10mg 
= 100ml), medium (35mg = 350ml) or high (60mg = 600ml) dose of isoflavones 
contained within a soy drink, by an independent clinical trials manager using MINIM 
software37, a placebo with no isoflavones was not available, a low dose was used that 
has not been previously shown to have a beneficial effect on menopausal 
symptoms50,51,57.  Participants were recommended to consume a specific volume of 
their soy drinks throughout each day for 12 weeks.  This approach provided the 
opportunity to look at doses that are commercially available and can be incorporated 
into the daily diet and is comparable to previous studies32.    Mood and menopausal 
symptoms were re-assessed post-intervention. Researchers contacted participants 
throughout the study and monitored their progress intermittently.   
 Compliance was monitored by measuring plasma concentrations of soy 
isoflavones, using LC-MS/MS by LGC Limited (Cambridgeshire, UK). Participants 
were instructed to consume the amounts across each day, rather than at once, as 
previous research suggests it is more effective at reducing menopausal symptoms38. 
The study was registered at https://www.clinicaltrials.gov (NCT03561662). 
 
Variables 
 All questionnaires used in this study, except for the MMSE which was 
administered by the researcher, were self-report.  
 Sociodemographic variables (age, education, BMI and menopause history), 
health, lifestyle and menopausal status were assessed using a questionnaire 
employed in previous studies based on the EPIC Health and Lifestyle Questionnaire, 
and adapted by Simpson et al.40.   
 An indication of cognitive decline was assessed using the Mini Mental State 
Examination41.  Scores are classified as 24-30 no cognitive impairment, 18-23 mild 
cognitive impairment, and 0-17 severe cognitive impairment.  The current study 
participant inclusion criteria was set at no impairment.  
 Screening for psychological distress was assessed using The General Health 
Questionnaire-28 (GHQ-28)42, a 28-item scale with four subscales assessing somatic 
symptoms, anxiety/insomnia, social dysfunction and severe depression. For inclusion 
in the current study, a total score of 26 or less was required (the GHQ-28 cut-off for 
distress).  
 Mood was assessed using The Positive and Negative Affect Schedule 
(PANAS)20 a 20-item scale comprised of 10 items assessing PA (e.g. happy, alert) 
and 10 items measuring NA (e.g. nervous, irritable). PA is associated with feelings of 
alertness, enthusiasm and happiness and NA with displeasure and dissatisfaction. 
These are regarded as higher-level mood states, accounting for the majority of the 
variance in discrete moods21. Momentary mood was measured four times a day for 
four consecutive days: upon rising; at 14.30; after dinner (17.00-18.00) and at 22.30, 
at baseline and follow up. The scales have high internal consistency, with Cronbach’s 
alpha ranging from .84 to .90 for PA scale and .84 to .87 for NA scale43 and proven 
validity20. The dependent trait measures of affect were based on overall intra-individual 
means and SDs for PA and NA for the four days.  
 Menopausal symptoms were assessed by the 21 item Greene Symptom 
Checklist44 measuring psychological, somatic, and vasomotor symptoms. Each item 
was rated on a 4 point Likert scale (0 = not at all, 1 = a little, 2 = quite a bit, 3 = 
extremely), a higher score being indicative of greater severity of symptoms. It has 
proven reliability for each subscale (test retest reliabilities of:  r = .87 for psychological; 
r = .84 for somatic and r = .83 for vasomotor) and content and construct validity45.  
 
Data analyses 
 Statistical analyses were performed using the Statistical Package for Social 
Sciences (SPSS) version 24. Prior to data analyses, the psychological data were 
checked for normality by first examining statistics for skewness and kurtosis which 
were within an acceptable range46.  Plasma isoflavones were analyzed using Kruskal-
Wallis with post-hoc Mann-Whitney U Tests. A series of 2 (time: baseline and follow-
up) * 3 (Dose: low medium and high isoflavones) ANOVA with repeated measures 





 A total of 101 postmenopausal women completed the study. As the original 
power calculation was based on cognition, a retrospective one was carried out to 
confirm the sample size required for mood, based on a small effect size of .2, found in 
previous study on mood and dietary intervention39, with a power of 0.8 and a 0.05 level 
of significance, 66 participants were required. An overview of the age range across 
the groups and educational level in each group is given in Table 1. Participants were 
within an expected age range for menopause, with just over half of the sample 
achieved tertiary level education.   
 
Compliance with soy intervention 
 Compliance was assessed by plasma isoflavone concentrations and is given in 
(Table 2).  Blood samples were available for isoflavones analysis for 95 participants 
at baseline and 87 post-intervention. There were no differences found for Isoflavones 
concentrations between the groups at baseline. At follow up, genistein concentration 
was higher in the medium (P = 0.007) and high (P = 0.013) dose groups compared to 
the low dose group. Post-intervention daidzein was higher in the medium (P = 0.006) 
and high (P = 0.029) dose groups compared to the low dose group. No group 
differences were noted post-intervention for isoflavone concentrations. Feedback from 
participants following the intervention showed the majority adhered to the dose given 
and were creative in adding it to their diet, in coffee, tea, porridge and puddings.  Those 
that had experienced problems with consumption of the specified volume were more 
likely to be from the high dose, with seven women failing to complete the intervention 
for this reason.  
 
The effect of dietary soy on mood  
 In order to determine the dietary soy intervention effect on mood and 
menopausal symptoms, repeated measures ANOVAs were carried out. These aimed 
to determine the change in mood (stability and variability) and menopausal symptoms 
over time, group differences between the three soy isoflavone doses and interaction 
effects to detect the impact of the soy intervention.  An overview of the results is given 
in Table 3 and will now be discussed in turn. 
 
Mood stability and dietary soy 
 Stability of mood was established by calculating the means of the 16 measures 
of PA and the 16 measures of NA recorded separately for baseline and follow-up. 
There were no changes in mood from baseline to post intervention for PA (F (1, 70) = 
1.10, P = 0.296) or NA (F(1,70) = 0.42, P = 0.521).There was a difference between the 
groups for dose for PA (F(2,70) = 6.6, P = 0.002), Bonferroni post hoc tests showed that 
low dose (M = 24.2) differed significantly from the medium dose (M = 29.7), with the 
latter reporting higher PA scores (P = 0.002). There was a difference between the 
groups for NA (F(2,70) = 3.12, P = 0.05), Bonferroni post hoc tests showed that low dose 
(M = 11.6) differed significantly from the high dose (M = 10.6), with the latter reporting 
lower NA scores (P = 0.048). There were no interaction effects for time and dose for 
PA (F(2,70) = .95, P = 0.390) and NA (F(2,70) = 0.72, P = 0.489). 
 
Mood variability and dietary soy 
 Mood variability is established by looking at the SD of the 16 PA and 16 NA 
measures recorded separately at baseline and follow up.  There were no differences 
in mood variability from baseline to follow up for PA variability (F(1, 70) = .35, P = 0.555) 
and NA variability (F (1, 70) = .49, P = 0 .488).  There were no between group differences 
for dose for either PA variability (F (1, 70) = 1.46, P = 0.240) or NA variability (F (1, 70) = 
2.83, P = 0.066), nor were there interaction effects for time by dose for PA variability 
(F (2, 70) = .21, P = 0.807) or NA variability (F (2,70) = .15, P = 0.864). 
 
Menopausal symptoms and dietary soy 
 There were reduced menopausal symptoms between baseline and follow up 
for vasomotor (baseline M = 4.2 and follow up M = 3.6)  (F (1, 89) = 9.10, P = 0.003), 
psychological (baseline M = 18 and follow up M = 16.5)  (F (1,88) = 8.34, P = 0.005) and 
total symptoms (baseline M = 34 and follow up M = 32)  (F (1,86) = 9.02, P = 0.004), 
and no change in somatic symptoms over time (F (1,89) = 1.59, P = 0.210).  There were 
no between group differences for dose for vasomotor (F (2,89) = 2.35, P = 0.102), 
psychological (F (2,88) = 0.69, p = 0.502), somatic (F (2,89) = 0.16, P = 0.848) or total (F 
(2,86) = 0.53, p = 0.590) menopausal symptoms. Nor were there any interaction effects 
for vasomotor (F (2,89) = 2.83, P = 0.064), psychological (F (2,88) = 0.63, P = 0.535), 




 To our knowledge this is the first randomized trial looking at the effects of dietary 
soy on everyday mood stability and variability of PA and NA.  In the current study, 
mood was assessed at baseline and post intervention, using 16 repeated measures 
of mood (four times a day for four consecutive days), employing a well-established 
method47, and addressing a methodological weakness in other studies8. The findings 
suggest that doses of soy (isoflavones 10, 35 and 60mg/day) used in this study had 
no effect on stability (mean) or variability (SD) of everyday PA or NA, nor on 
menopausal symptoms.  
 Isoflavones had no effect on everyday mood in this study, in keeping with 
previous dietary soy studies looking at general measures of quality of life and 
psychological well-being at menopause34-36. Similarly, using a protocol comparable to 
the current study, supplementation with 60 mg isoflavones (capsules) per day for 
either 6 or 12 weeks, had no effect on menopausal symptoms or mood assessed using 
visual analogue scales(VAS)48,49. However, our findings are contradictory to other soy 
interventions,  (isoflavone consumption ranged from 60mg/d to 160mg/d) that reported 
improvements in quality of life and psychological symptoms in postmenopausal 
women31,50,51. The amount of soy in the current study is comparable to some 
studies36,48,49,51, but lower than in others34,50. The amount consumed in the current 
study for the medium and high doses are within the recommended dose for 
management of menopausal symptoms by the EFSA guidelines57, which recommends 
35-150mg/day. However, the doses used in the current study may not have been 
taken for long enough as another intervention found 60mg/d of isoflavones taken for 
6 months had a beneficial effect on VAS mood post intervention51.  
 There was no change in menopausal symptoms post intervention. Most of the 
women in the current study were all post-menopausal for 3 years or more prior to 
taking part in the study. Menopausal symptoms were much lower than reported for a 
sample of recently menopausal women, just 12 months cessation of menses 58. The 
means and SD for PA and NA are comparable to previous research looking at older 
women aged 55-70 years47. Previous research looking at MT suggests that women 
are more at risk of mood disturbances during the perimenopausal phase, where 
hormone fluctuations and increased menopausal symptoms52 may result in a “window 
of vulnerability”, characterized by increases in NA and depressive symptoms53. 
Therefore, in the current study we may have missed this most turbulent time occurring 
closer to MT15 (from peri into post menopause), this may be the time that dietary soy 
could benefit mood. As women progress through MT into postmenopause, hormone 
levels become more stable and symptoms begin to subside, with improvements in PA 
and reduced NA being observed15.  There are a number of methodological issues that 
make comparisons between the studies of mood and menopause difficult.  Much of 
the research utilizes women from a range of ages, severity of menopausal symptoms 
and at different stages in MT8. There is no consistency in the assessment of mood, 
with many studies relying on one off measures, or using menopause symptom scales 
or quality of life measures as proxy mood assessments.  
 This study has several strengths, it is a randomized trial which is regarded as 
the gold standard when designing interventions and addressed a paucity of research 
looking at the effects of soy and psychological well-being in menopause31. The 
researchers believe this may be the first study to examine everyday mood assessed 
prospectively over four days at baseline and four days at post intervention, in 
postmenopausal women looking at the effect of soy on its stability and variability. We 
used self-report and well-established clinical hormone assessment to determine 
menopausal status. The use of well-established and validated repeated measures of 
mood is also a strong support for the study20 and has been validated in previous 
dietary intervention trials on healthy older adults39,47.  
 The study has limitations that need to be considered. Although the researchers 
adhered to very strict inclusion and exclusion criteria and stringent screening methods, 
this sample were healthy, with no major physical or mental health problems and may 
not be representative of all postmenopausal women.  As a consequence, those from 
lower socio-economic groups may have been excluded, this may be supported by over 
half of the sample completing tertiary level education. The sample size is also small 
but is adequately powered to look at changes in mood following a dietary intervention. 
Future studies need to be carried out on women nearer to MT and on a more 
representative sample before any firm conclusions can be drawn.  We have not 
considered other lifestyle factors and stress that have the potential to impact on mood 
and quality of life in menopause3. Also, personality variables have been found to be 
related to mood and were not assessed in the current study54. The duration of the 
intervention may not have been long enough to see a change in mood50. Also, the 
current study did not have a placebo condition which may have impacted on our 
findings as all the groups received some isoflavones, a placebo was not available to 
the researchers. The low dose was selected as it had not been found previously to 
impact on menopausal symptoms or well-being and was well below that recommended 
for use in menopause symptom management57. Another factor that was not 
considered in this study, but has the potential to impact on our findings, is the 
possibility of individual differences in the ability to metabolize isoflavones e.g. 
approximately one third of the population produce equol, a metabolite of soy derived 
from daidzein56 that alleviates vasomotor symptoms59,60. This may have contributed to 
some of the conflicting findings in studies looking at dietary soy intervention on quality 
of life36,50. Future studies need to consider this in relation to the impact of soy on 
psychological variables such as mood. 
 
CONCLUSION 
 A commercially available soy drink, containing 10, 35 and 60 mg/day of 
isoflavones, and consumed for 12 weeks in a sample of postmenopausal women, did 
not produce an effect on mood or menopausal symptoms. Results from research 
examining MT, peri to postmenopause, with increased fluctuations in hormones and 
symptoms, may reflect a window of vulnerability in some women and identify a key 
time for soy intervention.  Future studies need to consider this key MT phase and the 
differences in the effect of soy supplementation for equol and non-equol producers, 
on symptoms and psychological well-being. 
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Table 1 Sample characteristics for age and education level 
 Soy isoflavone treatment group 
Measure Low (n=35)  Medium (n=37)  High (n=29) 
Age in years 
Mean (SD) 
53.69 ± 3.72  53.86 ± 3.28  53.72 ± 4.62 
Education level 
(n)a 
Primary  0  1  0 
Secondary 19  13  12 
Tertiary 15  21  16 
a Data on education was unavailable for 4 participants (n = 1, n = 2 and n= 1 in the low, medium and high dose groups respectively) 




Table 2. Plasma isoflavone concentrations for genistein and daidzein at baseline and 
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Table 3. Means (SD) for mood measures and menopausal symptoms at baseline and follow up, showing effects for time, dose and interactions  
 
 
               Baseline                   12-week Follow up P value 
           Isoflavone dose          Isoflavone dose  
                                                                 Low        Medium       High  Low        Medium       High Time           Dose            Time X Dose 
PA mood mean 
PA mood SD 
NA mood mean 





24.2(6)     29.7(7)        25.3(5)                    
6.2(2)       7.5(5.3)       6.6(2) 
11.7(2)     10.9(1)        10.6(1) 
1.8(2)       1.4(2)          .95(1) 
18.3(4)     18.5(5)        17.2(4) 
9.8(2)       9.7(2)          9.8(3)  
4.5(2)       4.5(2)          3.6(1) 
34.6(6)     34.8(7)         32.9(7) 
24.2(7)     29.7(6)      27.6(7)    
6.3(3)       7.2(3)        5.9(3) 
11.6(2)     11.3(1)      10.7(1) 
2(2)          4.6(1)        .96(.8) 
17.3(4)     16.4(4)      16.2(3) 
9.1(2)       9.4(2)         9.7(3) 
4.0(2)       3.4(1)         3.5(2) 
32.7(7)     31.1(6)       31.4(7) 
    0.296             0.002                 0.390  
    0.555             0.240                 0.807 
    0.521             0.050                 0.489 
    0.488             0.066                 0.864 
    0.005             0.502                 0.535 
    0.210             0.848                 0.729 
    0.003             0.102                 0.064 
    0.004             0.590                 0.458 
    
Mean (SD) given for all values, except P. Differences for time: changes in the variables between baseline and follow up.  Dose: between group difference for 
low (10mg) medium (35mg) and high (60mg) isoflavone and 2 (time) X 3 (dose) interactions. Significant P values are accepted as < 0.005. N values changed 
for mood and menopausal symptoms across the groups in the analysis as the datasets were not complete across the two time points, for mood the ANOVA 
are based on: Low (n = 29), Medium (n = 26) and High (n = 18) and for menopausal symptoms the ANOVA are based on: Low (n = 33), Medium (n = 34) and 
High (n=24).  Mood mean = the mean of the 16 measures taken to represent respective mood types and represents the extent to which mood is stable over 
 
 




Assessed for Eligibility (n=394) 
Excluded  (n=279) 
Not meeting inclusion criteria (n=146) 





























Due to the size of treatment 
(n=7) 
Sickness in family (n=1) 
Breast Cancer (n=1) 
Analyzed  (n=35) Analyzed (n=37) Analyzed  (n=29) 
